{
    "clinical_study": {
        "@rank": "75572", 
        "arm_group": [
            {
                "arm_group_label": "Buscopan\u00ae (hyoscine butylbromide)", 
                "arm_group_type": "Experimental", 
                "description": "1st injection of Buscopan\u00ae solution 20mg, if necessary 2nd injection after 20min of the 1st injection"
            }, 
            {
                "arm_group_label": "654-II(anisodamine)", 
                "arm_group_type": "Active Comparator", 
                "description": "1st injection of 654-II solution 10mg, if necessary 2nd injection after 20min of the 1st injection"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to assess the efficacy of Buscopan\u00ae (hyoscine butylbromide) in\n      comparison to 654-II (anisodamine)in acute gastric or intestinal spasm-like pain."
        }, 
        "brief_title": "Efficacy of Buscopan\u00ae in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Intestinal Diseases", 
        "condition_browse": {
            "mesh_term": "Intestinal Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Patients must sign and date an Informed Consent consistent with International\n             Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) guidelines and local\n             regulation prior to participation in the trial.\n\n          2. Patients must agree to cooperate with all trial evaluations and perform all required\n             tasks.\n\n          3. Patients with acute gastric or intestinal spasm-like pain (without severe vomiting\n             and surgical acute abdomen).\n\n          4. Male or female patients aged 18 to 70 years.\n\n          5. The pain intensity upon screening is at least point 6 on a 0-10 numerical rating\n             scale (NRS).\n\n        Exclusion criteria:\n\n          1. Patients with the following concomitant disease is not eligible for enrollment:\n\n               -  Painful gastric or intestinal spasm of organic origin such as Crohn's disease,\n                  ulcerative colitis, lactose intolerance, gastrointestinal perforation, suspected\n                  gastrointestinal perforation or peritoneal effusion.\n\n               -  Pain related with malignancy.\n\n               -  Patients with other severe pain states of organic origin.\n\n               -  Mechanical stenosis of the gastrointestinal tract ,megacolin.\n\n               -  Urinary retention associated with mechanical stenosis of urinary tract.\n\n               -  Narrow-angled glaucoma.\n\n               -  Tachyarrhythmia.\n\n               -  Myasthenia gravis.\n\n               -  Meulengracht-Gilbert syndrome.\n\n               -  Known depression or known mental illness, anxiety disturbance.\n\n          2. Patients taking the following concomitant medication within 7 half-life of\n             concomitant medication  (the duration from taking concomitant medication to attending\n             the trial is less than 7 half-life) are not eligible for enrollment:\n\n               -  Analgesics,\n\n               -  Spasmolytics,\n\n               -  Anticholinergics\n\n               -  Affecting gastrointestinal motility, such as propantheline, metoclopramide,\n                  cisapride, loperamide, diphenoxylate, opioid analgesics, antacids and other\n                  ulcer treatment\n\n               -  Regular administration of laxatives\n\n               -  Narcotics\n\n               -  Antidepressant treatment or treatment with psychoactive drugs\n\n          3. Pregnancy and/or lactation or planned pregnancy;\n\n          4. Known hypersensitivity to N-butylscopolammonium bromide\n\n          5. Alcohol, or drug abuse.\n\n          6. Simultaneous participating in another clinical trial, or discontinuing from another\n             clinical trial before randomization (administration of study medication); moreover,\n             in the case of screening failure or premature discontinuing from the trial, repeated\n             enrollment is forbidden.\n\n          7. Unwilling to or unable to complete the entire trial procedure according to the\n             protocol.\n\n          8. In investigator's opinion, the patient is not proper for the trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "296", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01929044", 
            "org_study_id": "202.848"
        }, 
        "intervention": [
            {
                "arm_group_label": "654-II(anisodamine)", 
                "description": "10mg injection", 
                "intervention_name": "654-II (anisodamine)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Buscopan\u00ae (hyoscine butylbromide)", 
                "description": "20mg injection", 
                "intervention_name": "Buscopan\u00ae (hyoscine butylbromide)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Butylscopolammonium Bromide", 
                "Anisodamine", 
                "Scopolamine"
            ]
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baotou", 
                        "country": "China"
                    }, 
                    "name": "202.848.86016 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "202.848.86009 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "202.848.86008 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "202.848.86013 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "202.848.86010 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changchun", 
                        "country": "China"
                    }, 
                    "name": "202.848.86012 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China"
                    }, 
                    "name": "202.848.86007 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "202.848.86006 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China"
                    }, 
                    "name": "202.848.86003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "202.848.86002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "202.848.86011 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "202.848.86001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China"
                    }, 
                    "name": "202.848.86015 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shijiazhuang", 
                        "country": "China"
                    }, 
                    "name": "202.848.86014 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China"
                    }, 
                    "name": "202.848.86005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China"
                    }, 
                    "name": "202.848.86004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yangzhou", 
                        "country": "China"
                    }, 
                    "name": "202.848.86017 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Independent 3rd Party Unblind, Active-controlled, Parallel-group, Multi-center Trial, in Contrast With Anisodamine (654-II), 10mg, to Evaluate the Efficacy and Safety of Buscopan\u00ae Solution for Injection, 20mg (Intramuscularly) for the Treatment of Acute Gastric or Intestinal Spasm-like Pain", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pain intensity difference (PID) from pre-dose baseline at 20 minutes after the first injection.", 
            "safety_issue": "No", 
            "time_frame": "baseline and 20min"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01929044"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "PID from pre-dose baseline at 10, 30, 60 and 120 minutes after the first injection.", 
                "safety_issue": "No", 
                "time_frame": "up to 120min"
            }, 
            {
                "measure": "Global assessment of efficacy by the patient  at 120 minutes after the first injection using a 4-point rating scale (0=poor; 1=fair; 2=good; 3=very good).", 
                "safety_issue": "No", 
                "time_frame": "120min"
            }, 
            {
                "measure": "Proportion of patients who need the second injection at 20 minutes after the first injection.", 
                "safety_issue": "No", 
                "time_frame": "20min"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}